Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...

Amgen's stock plummeted to its lowest point in a year, experiencing a dramatic 10% drop to $264.59 in early trading following the release of disappointing results from its Maritide obesity treatment ...

Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

After Amgen (AMGN) announced topline data from its Phase 2 study of MariTide, the company’s subcutaneously administered GLP-1 weight loss drug, ...

Wall Street stocks, led by S&P 500 and the Nasdaq, ended higher on Tuesday, as technology stocks rebounded, while investors ...

Amgen Obesity Drug Cut Weight In Closely Watched Study Study subjects taking the company's MariTide lost about 20% of their weight in the 52-week trial. Novo Nordisk Says White House Obesity Plan Is ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street. Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide's latest ...